Inhibition of Breast Cancer Proteins by the Flavonoid Naringenin and its Derivative: A Molecular Docking Study


Affiliations

  • Periyar Maniammai Institute of Science and Technology, Department of Biotechnology, Thanjavur, Tamil Nadu, 613403, India
  • Bharathidasan University, Department of Biochemistry, Tiruchirappalli, Tamil Nadu, 620024, India

Abstract

Cancer is a multifaceted disease and is a major health burden in the world. Breast cancer is leading cause of mortality among women worldwide. Plant derived compounds have also been used in the treatment of cancer. Amongst them, flavonoids have been well documented for their therapeutic potential against cancer cells. Naringenin is a flavanone abundantly available in grapefruit and tomato among other sources. Several natural and synthetic derivatives of naringenin have been reported for anticancer activity. In this study, naringenin (Nar) and its derivative, naringenin 2-hydroxy benzoyl hydrazone (Nar-Bhz) were studied for their inhibitory potential against proteins involved in breast cancer. Molecular docking simulation by AutoDock was utilized to investigate the interaction of Nar and Nar-Bhz with Survivin, Estrogen receptor ? (ER?), progesterone receptor (PR), Akt1, and Epidermal growth factor receptor (EGFR). Doxorubicin was used as positive control because of its clinical importance in breast cancer treatment. Discovery Studio Visualizer was used to visualize the interactions and the docking results showed that the protein ligand complexes were stabilized by hydrogen bonding and hydrophobic interactions. The binding energies ranged between -7.66 to -7.91 kcal/mol with Nar-Bhz and between -5.49 and -11.05 kcal/mol for Nar. Significant inhibition constant was observed for Nar-Bhz interaction with Akt1 and EGFR. Also, several residues of Akt1 interacted with both the ligands. It can be concluded that naringenin and its derivative have promising inhibitory potential against the breast cancer proteins. The findings of this study may pave the way for detailed exploration of naringenin as breast cancer drug and as a nutraceutical or dietary supplement in daily intake.

Keywords

Breast Cancer, Docking, Flavonoids, Molecular, Naringenin, Naringenin Derivative

Full Text:

References

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J. Clin. 2021; 71(3):209–49. https://doi.org/10.3322/caac.21660. PMid:33538338

McPherson K, Steel CM, Dixon JM. ABC of breast diseases: Breast cancer-epidemiology, risk factors, and genetics. BMJ: Br. Med. J. 2000; 321(7261):624. https://doi.org/10.1136/bmj.321.7261.624. PMid:10977847. PMCid:PMC1118507

Stuckey A. Breast cancer: Epidemiology and risk factors. Clin. Obstet. Gynecol. 2011; 54(1):96–102. https://doi.org/10.1097/GRF.0b013e3182080056. PMid:21278508

Yuan E, Liu B, Ning Z, Chen C. Preparative separation of flavonoids in Adinandra nitida leaves by high-speed counter-current chromatography and their effects on human epidermal carcinoma cancer cells. Food Chem. 2009; 115(3):1158–63. https://doi.org/10.1016/j.foodchem. 2009.01.009

Ravishankar D, Rajora AK, Greco F, Osborn HMI. Flavonoids as prospective compounds for anti-cancer therapy. Int. J. Biochem. Cell Biol. 2013; 45(12):2821–31. https://doi.org/10.1016/j.biocel.2013.10.004. PMid:24128857

Kumar S, Pandey AK. Chemistry and biological activities of flavonoids: An overview. Sci. World J. 2013; 2013:162750. https://doi.org/10.1155/2013/162750. PMid:24470791. PMCid:PMC3891543

Rodriguez-Mateos A, Vauzour D, Krueger CG, Shanmuganayagam D, Reed J, Calani L, et al. Bioavailability, bioactivity and impact on health of dietary flavonoids and related compounds: An update. Arch. Toxicol. 2014; 88(10):1803–53. https://doi.org/10.1007/s00204-014-1330- 7. PMid:25182418

Zhao J, Zhang J, Yu M, Xie Y, Huang Y, Wolff DW, et al. Mitochondrial dynamics regulates migration and invasion of breast cancer cells. Oncogene. 2013; 32(40):4814–24. https://doi.org/10.1038/onc.2012.494. PMid:23128392. PMCid:PMC3911914

Plochmann K, Korte G, Koutsilieri E, Richling E, Riederer P, Rethwilm A, et al. Structure-activity relationships of flavonoid-induced cytotoxicity on human leukemia cells. Arch. Biochem. Biophys. 2007; 460(1):1–9. https://doi.org/10.1016/j.abb.2007.02.003. PMid:17353006

Sghaier MB, Skandrani I, Nasr N, Franca MGD, Chekir- Ghedira L, Ghedira K. Flavonoids and sesquiterpenes from Tecurium ramosissimum promote antiproliferation of human cancer cells and enhance antioxidant activity: A structure-activity relationship study. Environ. Toxicol. Pharm. 2011; 32(3):336–48. https://doi.org/10.1016/j.etap.2011.07.003. PMid:22004952

Salehi B, Fokou PVT, Sharifi-Rad M, Zucca P, Pezzani R, Martins N, et al. The therapeutic potential of naringenin: A review of clinical trials. Pharmaceuticals. 2019; 12(1):1– 18. https://doi.org/10.3390/ph12010011. PMid:30634637. PMCid:PMC6469163

Chandrika BB, Steephan M, Kumar TRS, Sabu A, Haridas M. Hesperetin and Naringenin sensitize HER2 positive cancer cells to death by serving as HER2 Tyrosine Kinase inhibitors. Life Sci. 2016; 160:47–56. https://doi.org/10.1016/j.lfs.2016.07.007. PMid:27449398

Zhang F, Dong W, Zeng W, Zhang L, Zhang C, Qiu Y, et al. Naringenin prevents TGF-?1 secretion from breast cancer and suppresses pulmonary metastasis by inhibiting PKC activation. Breast Cancer Res. : BCR. 2016; 18(1):38. https://doi.org/10.1186/s13058-016-0698-0. PMid:27036297. PMCid:PMC4818388

Mir IA, Tiku AB. Chemopreventive and therapeutic potential of “Naringenin,” a flavanone present in citrus fruits. Nutr. Cancer. 2015; 67(1):27–42. https://doi.org/10.1080/01635581.2015.976320. PMid:25514618

Wang BD, Yang ZY, Wang Q, Cai TK, Crewdson P. Synthesis, characterization, cytotoxic activities, and DNA-binding properties of the La(III) complex with Naringenin Schiffbase. Bioorg. Med. Chem. 2006;14(6):1880–8. https://doi.org/10.1016/j.bmc.2005.10.031. PMid:16310358

Li T-R, Yang Z-Y, Wang B-D. Synthesis, characterization and antioxidant activity of naringenin Schiff base and its Cu(II), Ni(II), Zn(II) complexes. Chem. Pharm. Bull. (Tokyo). 2007; 55(1):26–8. https://doi.org/10.1248/cpb.55.26. PMid:17202696

Sun TM, Wang YC, Wang F, Du JZ, Mao CQ, Sun CY, et al. Cancer stem cell therapy using doxorubicin conjugated to gold nanoparticles via hydrazone bonds. Biomaterials. 2014; 35(2):836–45. https://doi.org/10.1016/j.biomaterials. 2013.10.011. PMid:24144908

Jiang T, Li YM, Lv Y, Cheng YJ, He F, Zhuo RX. Amphiphilic polycarbonate conjugates of doxorubicin with pH-sensitive hydrazone linker for controlled release. Colloids Surf. B. 2013; 111:542–8. https://doi.org/10.1016/j.colsurfb.2013.06.054. PMid:23893028

Nikolova-Mladenova B, Momekov G, Ivanov D, Bakalova A. Design and drug-like properties of new 5-methoxysalicylaldehyde based hydrazones with anti-breast cancer activity. J. Appl. Biomed. 2017; 15(3):233–40. https://doi.org/10.1016/j.jab.2017.04.004

Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, et al. Invasive breast cancer version 1.2016. JNCCN J. Natl. Compr. Cancer Netw. 2016; 14(3):324–54. https://doi.org/10.6004/jnccn.2016.0037. PMid:26957618

Garg H, Suri P, Gupta JC, Talwar GP, Dubey S. Survivin: A unique target for tumor therapy. Cancer Cell Int. 2016; 16(1):1–14. https://doi.org/10.1186/s12935-016-0326-1. PMid:27340370. PMCid:PMC4917988

Jia M, Dahlman-Wright K, Gustafsson JÅ. Estrogen receptor alpha and beta in health and disease. Best Pract. Res. Clin. Endocrinol. Metab. 2015; 29(4):557–68. https://doi.org/10.1016/j.beem.2015.04.008. PMid:26303083

Arnal JF, Lenfant F, Metivier R, Flouriot G, Henrion D, Adlanmerini M, et al. Membrane and nuclear estrogen receptor alpha actions: From tissue specificity to medical implications. Physiol. Rev.. 2017; 97(3):1045–87. https://doi.org/10.1152/physrev.00024.2016. PMid:28539435

Siersbæk R, Kumar S, Carroll JS. Signaling pathways and steroid receptors modulating estrogen receptor ? function in breast cancer. Genes Dev. 2018; 32(17–18):1141–54. https://doi.org/10.1101/gad.316646.118. PMid:30181360. PMCid:PMC6120708

Li X, O’Malley BW. Unfolding the action of progesterone receptors. J. Biol. Chem. 2003; 278(41):39261–4. https://doi.org/10.1074/jbc.R300024200. PMid:12893816

Osborne CK. Steroid hormone receptors in breast cancer management. Breast Cancer Res. Treat. 1998; 51(3):227–38. https://doi.org/10.1023/A:1006132427948. PMid:10068081

Shyamala G, Chou YC, Louie SG, Guzman RC, Smith GH, Nandi S. Cellular expression of estrogen and progesterone receptors in mammary glands: Regulation by hormones, development and aging. J. Steroid Biochem. Mol. Biol. 2002; 80(2):137–48. https://doi.org/10.1016/S0960-0760(01)00182-0

Datta SR, Brunet A, Greenberg ME. Cellular survival: A play in three akts. Genes Dev. 1999; 13(22):2905–27. https://doi.org/10.1101/gad.13.22.2905. PMid:10579998

Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N. Engl. J. Med. 2008; 358:1160–74. https://doi.org/10.1056/NEJMra0707704. PMid:18337605

Ioannou N, Seddon AM, Dalgleish A, Mackintosh D, Modjtahedi H. Expression pattern and targeting of HER family members and IGF-IR in pancreatic cancer. Front. Biosci. 2012; 17(4):2698–724. https://doi.org/10.2741/4081. PMid:22652808

Khelwatty SA, Essapen S, Seddon AM, Modjtahedi H. Prognostic significance and targeting of HER family in colorectal cancer. Front. Biosci. 2013; 18:394–421. https://doi.org/10.2741/4110. PMid:23276932

Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 2009; 30(16):2785– 91. https://doi.org/10.1002/jcc.21256. PMid:19399780. PMCid:PMC2760638

Raeisi S, Chavoshi H, Mohammadi M, Ghorbani M, Sabzichi M, Ramezani F. Naringenin-loaded nano-structured lipid carrier fortifies oxaliplatin-dependent apoptosis in HT-29 cell line. Process. Chem. 2019; 83:168–75. https://doi.org/10.1016/j.procbio.2019.05.013

Ryan BM, O’Donovan N, Duffy MJ. Survivin: A new target for anti-cancer therapy. Cancer Treat. Rev. 2009; 35(7):553–62. https://doi.org/10.1016/j.ctrv.2009.05.003. PMid:19559538

Taglieri L, De Iuliis F, Giuffrida A, Giantulli S, Silvestri I, Scarpa S. Resistance to the mTOR inhibitor everolimus is reversed by the downregulation of survivin in breast cancer cells. Oncol. Lett. 2017; 14(3):3832–38. https://doi.org/10.3892/ol.2017.6597. PMid:28927154. PMCid:PMC5587981

McGuire WL. Estrogen receptors in human breast cancer. J. Clin. Investig. 1973; 52(1):73–77. https://doi.org/10.1172/JCI107175. PMid:4345203. PMCid:PMC302228

Ali S, Mondal N, Choudhry H, Rasool M, Pushparaj PN, Khan MA, et al. Current management strategies in breast cancer by targeting key altered molecular players. Front. Oncol. 2016; 6(Mar). https://doi.org/10.3389/fonc.2016.00045

Colditz GA. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst. 1998; 90(11):814–23. https://doi.org/10.1093/jnci/90.11.814. PMid:9625169

Hankinson SE, Colditz GA, Willett WC. The lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Res. 2004; 6(5):213–18. https://doi.org/10.1186/bcr921. PMid:15318928. PMCid:PMC549181

Patel HK, Bihani T. Selective Estrogen Receptor Modulators (SERMs) and Selective Estrogen Receptor Degraders (SERDs) in cancer treatment. Pharmacol. Ther. 2018; 186:1– 24. https://doi.org/10.1016/j.pharmthera.2017.12.012. PMid:29289555

Kumar N, Gulati HK, Sharma A, Heer S, Jassal AK, Arora L, et al. Most recent strategies targeting estrogen receptor alpha for the treatment of breast cancer. Mol. Divers. 2021; 25(1):603–24. https://doi.org/10.1007/s11030-020-10133-y. PMid:32886304

Al-Bader M, Ford C, Al-Ayadhy B, Francis I. Analysis of estrogen receptor isoforms and variants in breast cancer cell lines. Exp. Ther. Med. 2011; 2(3):537–44. https://doi.org/10.3892/etm.2011.226. PMid:22977537. PMCid:PMC3440683

El-Kersh DM, Ezzat SM, Salama MM, Mahrous EA, Attia YM, Ahmed MS, et al. Anti-estrogenic and anti-aromatase activities of citrus peels major compounds in breast cancer. Sci. Rep. 2021; 11(1):1–14. https://doi.org/10.1038/s41598- 021-86599-z. PMid:33782546. PMCid:PMC8007834

So FV, Guthrie N, Chambers AF, Carroll KK. Inhibition of proliferation of estrogen receptor-positive MCF-7 human breast cancer cells by flavonoids in the presence and absence of excess estrogen. Cancer Lett. 1997; 112(2):127– 33. https://doi.org/10.1016/S0304-3835(96)04557-0

Mohammed H, Russell IA, Stark R, Rueda OM, Hickey TE, Tarulli GA, et al. Progesterone receptor modulates ER? action in breast cancer. Nature. 2015; 523(7560):313–17. https://doi.org/10.1038/nature14583. PMid:26153859. PMCid:PMC4650274

Wagenfeld A, Saunders PTK, Whitaker L, Critchley HOD. Selective progesterone receptor modulators (SPRMs): Progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapies. Expert Opin. Ther. Targets. 2016; 20(9):1045–54. https://doi.org/10.1080/14728222.2016.1180368. PMid:27138351. PMCid:PMC4989858

Miller TW, Rexer BN, Garrett JT, Arteaga CL. Mutations in the phosphatidylinositol 3-kinase pathway: Role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res. 2011; 13(6). https://doi.org/10.1186/bcr3039. PMid:22114931. PMCid:PMC3315683

Rao VV, Mane SR, Kishore A, Das Sarma J, Shunmugam R. Norbornene derived doxorubicin copolymers as drug carriers with pH responsive hydrazone linker. Biomacromolecules. 2012; 13(1):221–30. https://doi.org/10.1021/bm201478k. PMid:22107051

Shin SY, Yong Y, Kim CG, Lee YH, Lim Y. Deoxypodophyllotoxin induces G2/M cell cycle arrest and apoptosis in HeLa cells. Cancer Lett. 2010; 287(2):231–9. https://doi.org/10.1016/j.canlet.2009.06.019. PMid:19616373

Ju X, Katiyar S, Wang C, Liu M, Jiao X, Li S, et al. Akt1 governs breast cancer progression in vivo. Proc Natl Acad Sci USA. 2007; 104(18):7438–43. https://doi.org/10.1073/pnas.0605874104. PMid:17460049. PMCid:PMC1863437

Bak Y, Kim H, Kang J-W, Lee DH, Kim MS, Park YS, et al. A synthetic naringenin derivative, 5-Hydroxy-7, 4‘-diacetyloxyflavanone-N-phenyl Hydrazone (N101- 43), induces apoptosis through Up-regulation of Fas/FasL expression and inhibition of PI3K/Akt signaling pathways in non-small-cell lung cancer cells. J. Agric. Food Chem. 2011; 59(18):10286–97. https://doi.org/10.1021/jf2017594. PMid:21877710

Kim J-H, Kang JW, Kim MS, Bak Y, Park YS, Jung K-Y, et al. The apoptotic effects of the flavonoid N101-2 in human cervical cancer cells. Toxicology In Vitro. 2012; 26(1):67–73. https://doi.org/10.1016/j.tiv.2011.10.012. PMid:22056764

Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, et al. Review series ErbB receptors : from oncogenes to targeted cancer therapies. Molecules. 2007; 117(8):2051–8. https://doi.org/10.1172/JCI32278. PMid:17671639. PMCid:PMC1934579


Refbacks

  • There are currently no refbacks.